TY - JOUR
T1 - NF-B, inflammation, immunity and cancer
T2 - Coming of age
AU - Taniguchi, Koji
AU - Karin, Michael
N1 - Funding Information:
The authors thank S. Grivennikov (Fox Chase Cancer Center) for his comments. This work was supported by a Postdoctoral Fellowship for Research Abroad and Research Fellowship for Young Scientists from the Japan Society for the Promotion of Science (JSPS), the Uehara Memorial Foundation Fellowship, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Kanae Foundation for the Promotion of Medical Science, JSPS KAKENHI (JP15K21775), the ‘Kibou’ Projects, the Astellas Foundation for Research on Metabolic Disorders, the SENSHIN Medical Research Foundation, a grant from Bristol‑Myers Squibb, the SGH foundation, the MSD Life Science Foundation, the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, the Yasuda Medical Foundation, the Suzuken Memorial Foundation, the Pancreas Research Foundation of Japan, the Waksman Foundation of Japan Inc., the Japanese Foundation for Multidisciplinary Treatment of Cancer, the Toray Science Foundation, Project Mirai Cancer Research Grants from the Japan Cancer Society, a Research Grant of the Princess Takamatsu Cancer Research Fund and the Takeda Science Foundation (all to K.T.) as well as by the US National Institutes of Health (AI043477, CA219119, CA155120 and CA118165) to M.K., who is an American Cancer Society Research Professor and holder of the Benjamin G. and Wanda L. Hildyard Chair for Mitochondrial and Metabolic Diseases.
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature. All rights reserved.
PY - 2018/5/1
Y1 - 2018/5/1
N2 - Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a molecular lynchpin that links persistent infections and chronic inflammation to increased cancer risk. The young field of inflammation and cancer has now come of age, and inflammation has been recognized by the broad cancer research community as a hallmark and cause of cancer. Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumour-elicited inflammation and its effects on anticancer immunity.
AB - Fourteen years have passed since nuclear factor-κB (NF-κB) was first shown to serve as a molecular lynchpin that links persistent infections and chronic inflammation to increased cancer risk. The young field of inflammation and cancer has now come of age, and inflammation has been recognized by the broad cancer research community as a hallmark and cause of cancer. Here, we discuss how the initial discovery of a role for NF-κB in linking inflammation and cancer led to an improved understanding of tumour-elicited inflammation and its effects on anticancer immunity.
UR - http://www.scopus.com/inward/record.url?scp=85044512447&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044512447&partnerID=8YFLogxK
U2 - 10.1038/nri.2017.142
DO - 10.1038/nri.2017.142
M3 - Review article
C2 - 29379212
AN - SCOPUS:85044512447
SN - 1474-1733
VL - 18
SP - 309
EP - 324
JO - Nature Reviews Immunology
JF - Nature Reviews Immunology
IS - 5
ER -
